News
We bring you up to date at all times: Discover the latest news from the chemical industry, analytics, lab technology and process engineering. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of the chemical industry: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 64,557 keywords from chemistry, pharmaceutics, material sciences and related science disciplines in the encyclopedia.
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.chemeurope.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
15-Feb-2007 - Pfizer announced that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would represent significant improvements over current therapies. If approved by ...
05-Feb-2007 - Pfizer Inc announced that it has entered into an agreement to acquire BioRexis Pharmaceutical Corporation, a privately-held biopharmaceutical company with a number of diabetes candidates and a novel technology platform for developing new protein drug candidates. Financial terms of the agreement ...
Consortium to Drive the Evolution of Enterprise Cheminformatics Systems Using Open and Flexible Service-Oriented Architecture
05-Feb-2007 - Accelrys, Inc. announced the addition of Pfizer to the Accelrys Enterprise Cheminformatics Consortium. The Consortium will be a collaborative software development project led by Accelrys in partnership with a group of commercial member organizations. Its goal is to prioritize, design, and develop ...
22-Dec-2006 - Pfizer Inc said that it has completed the sale of its Pfizer Consumer Healthcare business to Johnson & Johnson for $16.6 billion or about $13.5 billion in after-tax proceeds. "The proceeds from this sale, combined with our strong operating cash flow, give us the flexibility to invest in the ...
New legislation threatens medicines
21-Nov-2006 - Europe's proposed new chemicals legislation, REACH, could disrupt the supply of important medicines. David Vosvenieks, REACH issue manager at AstraZeneca (AZ), told Chemistry & Industry that two companies supplying intermediates required for two AZ drugs - one of them an anticancer therapy - have ...
01-Aug-2006 - The Pfizer Board of Directors has named Jeffrey B. Kindler Pfizer's chief executive officer. He succeeds Hank McKinnell, who will remain Pfizer's chairman of the board until his retirement in February, 2007. Mr. Kindler has been elected to the Pfizer Board of Directors. Mr. Kindler currently ...
11-Nov-2005 - Pfizer Inc said that the Oslo District Court in Norway ruled that a Pfizer patent covering an intermediate compound used to make atorvastatin, the active ingredient in Lipitor, would be infringed by the sale of Ranbaxy Laboratories Ltd.'s proposed generic atorvastatin product in Norway. In ...
01-Nov-2005 - Pfizer and sanofi-aventis, a member of the sanofi-aventis Group, said that the U.S. Food and Drug Administration has notified the companies that it is extending its original review period for Exubera® (insulin [rDNA origin] powder for oral inhalation) by three months to review additional ...
16-Sep-2005 - Pfizer Inc completed its acquisition of Vicuron Pharmaceuticals Inc., a biopharmaceutical company focused on the development of novel anti-infectives for both hospital-based and community-acquired infections. In connection with the closing, shares of Vicuron common stock have been delisted from ...
17-Aug-2005 - Vicuron Pharmaceuticals announced that its stockholders have voted to approve the merger agreement pursuant to which Vicuron is being acquired by Pfizer. The closing of the transaction is expected to occur in the third quarter, subject to satisfaction of customary closing conditions, including ...
© 1997-2024 LUMITOS AG, All rights reserved